NCT03804866View on ClinicalTrials.gov

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Ovarian Cancer
Interventions
DRUG

NGR-hTNF

NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

DRUG

Pegylated liposomal doxorubicin

50 mg/m² iv every 4 weeks until confirmed evidence of disease progression

DRUG

Doxorubicin

60 mg/m² iv every 3 weeks for a maximum of 8 cycles

Trial Locations (4)

20132

Ospedale San Raffaele, Milan

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

Istituto Europeo di Oncologia, Milan

80131

"Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale", Naples

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY